Optimizing COVID-19 Treatment in Hospitalized Patients

Karine Lacombe, MD, PhD


December 02, 2022

The current treatment landscape for hospitalized patients with COVID-19 has changed dramatically since the early days of the pandemic. More treatment options, supported by key international studies such as the EPIC-HR, RECOVERY, and PINETREE trials, have provided clinicians with important evidence of safety and efficacy as well as treatment timing guidelines.

Early use of antiviral therapy and immunomodulatory medications now represents a vital component of treatment in patients who have been hospitalized due to COVID-19 or who were previously admitted for unrelated conditions and incidentally tested positive.

In this ReCAP, Karine Lacombe, MD, PhD, head of Department of Infectious Diseases at Hospital Saint-Antoine in Paris, France, discusses the specific subpopulations of patients who are most commonly hospitalized with COVID-19 today, and the most effective early treatment approaches on the basis of disease severity, including second-line therapeutic options.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.